Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to Read More
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- Read More
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
Data show MammaPrintยฎย is the first and most comprehensive FDA-cleared test Read More
Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Testsโ Utility to Identify Patients Who Will Benefit Most from Specific Treatments
Data demonstrate Research Use Only ImPrint testโs ability to identify Read More
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer
Company to present multiple recent Registry sub-studies driving cancer care Read More
Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Agendia to Deliver Robust Suite of Data Advancing Breast Cancer Care at ASCO 2022
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More
GenomeWeb – Agendia Offering AI-Enabled Genomic Test for Breast Cancer in Brazil as it Eyes Global Market
January 27, 2022 By Leo OโConnor NEW YORK โย As part Read More
Agendia Study Demonstrates MammaPrintยฎ and BluePrintยฎ Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
Agendia to Provide First Digital MammaPrint Capability to Brazil
AI solution will expand Agendiaโs testing platform in the Brazilian Read More
